Genocea Boosted By Biotech's Recent Rise After 12-Month Herpes Data Update
This article was originally published in Scrip
Genocea Biosciences Inc. is holding out hope that Phase II data from genital herpes patients treated with GEN-003 for 12 months will give the therapeutic vaccine a market advantage, and while the commercial potential is unclear given the mixed data the company reported on March 31, its stock price soared on the clinical trial update for its sole clinical drug candidate.
You may also be interested in...
Genocea shifts to preclinical neoantigen-based cancer vaccines rather than advance a Phase III-ready herpes program on its own and Mateon gives up on its lead drug as placebo outperforms. Also, Juno tops recent public company financings and new VC funds back early-stage firms.
New vaccines and a compound with new mechanism of action that are in early clinical trials suggest the poorly served antiherpes market could be rejuvenated in the next few years.
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.